Gene Kinney

#BreakingNews: Today, we’re excited to share that @novonordisk successfully completed a Phase 2 trial with coramitug (formerly PRX004) and is expected to advance the program into Phase 3 development for ATTR #amyloidosis with cardiomyopathy (ATTR-CM) in 2025. Read more: bit.ly/4opUx4T

Chad Swanson, Chief Development Officer, joined the “Improving the Therapeutic Potential of Immunotherapies in AD” session at #ADPD2025, where experts came together to discuss the latest research and strategies in slowing disease progression. We stand alongside the #AlzheimersDisease community and are committed to continued research, collaborate, and drive innovation for patients and their families.

In a conversation with President and CEO, Gene Kinney, we reflect on 2024, discuss what lies ahead for Prothena in 2025 and our ongoing commitment to developing therapies for patients affected by protein dysregulation. Learn more: bit.ly/41L4QqW

Participation in the AFFIRM-AL study will help us understand whether an investigational medication is effective for adults newly diagnosed with advanced AL #amyloidosis. Learn more about participating: bit.ly/4cXd2YA

As we enter 2025, our CEO Gene Kinney, highlights our ongoing commitment to supporting the millions affected by neurodegenerative & rare peripheral amyloid diseases. Here’s to a year of continued progress, collaboration, & meaningful impact for the patients & their loved ones.

As 2024 comes to a close, we reflect on a remarkable year at Prothena. We want to extend our warmest wishes for a happy and prosperous New Year to our Prothena family, partners in advocacy, and the patients and caregivers we serve. #HappyHolidays

#DYK NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend primary treatment for AL #amyloidosis is in a clinical trial? Visit our booth (2027) at #ASH24 to learn more about the AFFIRM-AL clinical trial in Mayo Stage IV AL amyloidosis.

Join us for our Friday Satellite Symposium, preceding #ASH24. We are proud to sponsor the independent Medscape CME Symposium, “Escape the Amyloid Maze: Unraveling Data and Care Strategies for AL Amyloidosis,” tomorrow at 11:30am PT.

This #WorldAmyloidosisDay, we stand with patients, families, and all others affected by this #raredisease. At Prothena, we remain deeply committed to advancing treatment options and making a difference for the #amyloidosis community.

AL #amyloidosis can be challenging to diagnose due to its varied symptoms. Hear from those impacted by this #raredisease and the challenges they faced in putting the puzzle pieces together: bit.ly/471coHi

This year, we proudly joined @Amyloidosisfdn's Virtual Run/Walk/Roll/Bike Event, spreading awareness in support of #amyloidosis within our local communities. Across the US and EU, our teams came together to participate in this impactful event! #RunForAmyloidosis

Collaborative partnerships are fundamental in driving innovation. Check out our discussion with @PharmaVoice on our transformative R&D efforts in partnership with @bmsnews, aimed at advancing treatments for CNS disorders: bit.ly/3zlE0Ke

Today's unanimous and positive FDA Peripheral and Central Nervous System Drugs Ad Comm vote marks a step forward in progress for patients, families, and caregivers in treating #Alzheimers disease.

An #amyloidosis diagnosis can leave patients & families with unanswered questions. We encourage you to check out @Amyloidosis_ARC’s patient resources to learn more about this condition & the support available to those impacted: arci.org/patient-resources/ #AmyloidosisAwarenessMonth

At Prothena, we believe it’s important to elevate firsthand perspectives from patients. Watch as Linda, living with #amyloidosis, offers advice for others who are managing this disease: bit.ly/4cvmpyS #AmyloidosisAwarenessMonth

An #amyloidosis diagnosis impacts the entire family. Mike, who is currently living with AL amyloidosis, discusses his wife’s role as a caregiver for him, and the unwavering support that she has offered throughout his experience with this #raredisease. #AmyloidosisAwarenessMonth

There is an urgent unmet need for therapies that address both the amyloid circulating and deposited in vital organs for those living with AL #amyloidosis. Learn more about our work in this area by visiting our pipeline: bit.ly/3x06KXT #AmyloidosisAwarenessMonth

In honor of #AmyloidosisAwarenessMonth, read as @Amyloidosisfdn President Mary O’Donnell discusses the organization’s work in AL #amyloidosis and why this awareness month matters: bit.ly/490dCll

In recognition of #AmyloidosisAwarenessMonth, we will be sharing #amyloidosis related content each day this week. We’re proud to support @Amyloidosisfdn and the amyloidosis community by illuminating our logo red all month long to spread awareness.